Therapy Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + Daraxonrasib + Pemetrexed Disodium + RMC-9805 |
| Synonyms | |
| Therapy Description | |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| Daraxonrasib | RMC 6236|RMC6236|RMC-6236 | RAS Inhibitor (Pan) 13 | Daraxonrasib (RMC-6236) forms a binary complex with CypA, which prevents GTP-bound RAS from interacting with downstream effectors, potentially leading to anti-tumor activity (Cancer Res 2022;82(12_Suppl): Abstract nr 3597, PMID: 38593348). | |
| Pemetrexed Disodium | Alimta | LY231514|Ciambra|pemetrexed | Chemotherapy - Antimetabolite 14 | Alimta (pemetrexed disodium) is an antifolate that inhibits thymidylate synthase (NCI Drug Dictionary). |
| RMC-9805 | RMC 9805|RMC9805 | KRAS G12D Inhibitor 25 | RMC-9805 inhibits KRAS G12D, which potentially results in reduced downstream signaling and proliferation, induction of apoptosis, and decreased tumor growth (Cancer Res 2023;83(7_Suppl):Abstract nr 526). |
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
Filtering
- Case insensitive filtering will display rows if any text in any cell matches the filter term
- Use simple literal full or partial string matches
- Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
- Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
- Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")
Sorting
- Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
- Click on any column header arrows to sort by that column
- Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06162221 | Phase Ib/II | Daraxonrasib + Pembrolizumab + RMC-6291 Cisplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Carboplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium Daraxonrasib + Pembrolizumab Cisplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium RMC-9805 Cisplatin + Daraxonrasib + Pemetrexed Disodium + RMC-9805 Carboplatin + Daraxonrasib + Pemetrexed Disodium + RMC-9805 Carboplatin + Daraxonrasib + Pembrolizumab + Pemetrexed Disodium + RMC-6291 Daraxonrasib + Pembrolizumab + RMC-9805 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Recruiting | USA | NLD | ITA | GRC | FRA | ESP | DEU | AUS | 1 |
CKB BOOST